4 Results for "

Malignant neoplasms

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "Malignant neoplasms" in MCE Product Catalog:

Cat. No.: HY-N15754
CAS No.: 54665-33-7
3-Hydroxy-2-methylglutaric acid is a carboxylic acid metabolite. 3-Hydroxy-2-methylglutaric acid can be isolated from the flower Veronica incana L. 3-Hydroxy-2-methylglutaric acid can be used for upper respiratory tract diseases, malignant neoplasms, gastrointestinal tract and genitourinary system disorders and diabetes mellitus research .
loading...
    loading...
Cat. No.: HY-122712
CAS No.: 61034-15-9
Target:  

Drug Derivative

Research Areas:  

Cancer

CB-002 is an active molecule that can be used for the study of advanced malignant solid neoplasm .
loading...
    loading...
Cat. No.: HY-L184
1,203 compounds

Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.

MCE designs a unique collection of 1,203 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Cat. No.: HY-L025
11,237 compounds

Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc.

MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.